Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 Aug 9, 2023 08:00AM
Precigen (PGEN) Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval Aug 9, 2023 07:05AM
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval Aug 9, 2023 07:05AM
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th Aug 3, 2023 04:05PM
Precigen Inc. (PGEN) Granted FDA Breakthrough Therapy Designation for PRGN-2012 Jun 20, 2023 07:30AM
View Older Stories

Jun 20, 2023 07:30AM Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Jun 5, 2023 04:06PM Precigen Inc. (PGEN) Reports Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells
Jun 5, 2023 04:05PM Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
Jun 5, 2023 05:55AM Precigen Inc. (PGEN) Presents Positive Phase 1 Data for Off-the-Shelf PRGN-2009
Jun 3, 2023 12:00PM Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metast
May 31, 2023 08:05AM Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Ce
May 10, 2023 08:00AM Precigen Reports First Quarter 2023 Financial Results and Business Updates
Apr 26, 2023 04:05PM Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting
Apr 17, 2023 09:02AM Precigen Inc. (PGEN) Presents Preclinical Data
Apr 17, 2023 09:01AM Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
Apr 3, 2023 04:31PM Precigen Inc. (PGEN) Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T
Apr 3, 2023 04:30PM Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®
Mar 29, 2023 08:06AM Precigen (PGEN) Reports First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007
Mar 29, 2023 08:05AM Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumor
Mar 28, 2023 08:05AM Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium
Mar 6, 2023 04:05PM Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Jan 12, 2023 04:58AM Precigen (PGEN) Provides Pipeline and Corporate Updates
Jan 11, 2023 06:45PM Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
Dec 19, 2022 04:05PM Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 12, 2022 07:01PM Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
Nov 9, 2022 04:05PM Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
Nov 2, 2022 04:30PM Precigen to Announce Third Quarter 2022 Financial Results on November 9th
Sep 21, 2022 04:31PM Precigen (PGEN) Appoints Rutul R. Shah as COO
Sep 21, 2022 04:31PM Precigen (PGEN) Appoints Rutul R. Shah as COO
Sep 21, 2022 04:30PM Precigen Names Rutul R. Shah Chief Operating Officer
Sep 1, 2022 08:05AM Precigen to Participate in the 2022 Wells Fargo Healthcare Conference
Aug 22, 2022 08:05AM Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
Aug 8, 2022 04:05PM Precigen Reports Second Quarter and First Half 2022 Financial Results
Aug 1, 2022 04:05PM Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th
Jul 5, 2022 08:05AM Precigen Inc. (PGEN) to Divest Non-Healthcare Subsidiary Trans Ova Genetics
Jul 5, 2022 08:05AM Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
Jun 27, 2022 04:05PM Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit
May 17, 2022 04:05PM Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference
May 9, 2022 04:05PM Precigen Reports First Quarter 2022 Financial Results and Business Updates
Apr 4, 2022 08:05AM Precigen Inc. (PGEN) Granted Fast Track Designation for PRGN-3006 UltraCAR-T
Apr 4, 2022 08:05AM Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Mar 1, 2022 08:00AM Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
Jan 12, 2022 04:32PM Precigen Inc. (PGEN) Announces Corporate and Pipeline Update
Jan 12, 2022 04:30PM Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Jan 5, 2022 04:05PM Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 13, 2021 05:06PM Precigen Inc. (PGEN) Reports Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T in Relapsed or Refractory Acute Myeloid Leukemia
Dec 13, 2021 05:05PM Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia
Nov 10, 2021 04:05PM Precigen to Present at the Stifel 2021 Virtual Healthcare Conference
Nov 4, 2021 09:15AM Precigen Inc. (PGEN) Reports Significant Clinical Progress for UltraCAR-T and AdenoVerse Therapies
Nov 4, 2021 09:15AM Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies
Oct 27, 2021 04:38PM Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments
Oct 26, 2021 08:05AM Precigen Inc. (PGEN) Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors
Oct 26, 2021 08:05AM Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors
Oct 12, 2021 08:06AM Precigen Inc. (PGEN) Appoints Harry Thomasian Jr as CFO
Oct 12, 2021 08:05AM Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer
View Older Stories